APPLICATION OF MOLECULAR DOCKING AND CADD IN NEURODEGENERATIVE DISEASES

Abstract
NDs (neurodegenerative diseases), including Alzheimer's disease, Parkinson's disease,
amyotrophic lateral sclerosis and Huntington's disease, are some of the most common chronic
illnesses worldwide. These disorders mainly affect the brain and nervous system; at this time,
there is no complete treatment available for any type of NDs. Finding effective treatments for
NDs continues to be a major challenge in medical research. The use of computer-aided drug
design (CADD) has become an essential resource for drug discovery today. By allowing
scientists to identify and sort potential drug compounds through computer-based techniques
prior to laboratory testing, CADD can significantly reduce the number of compounds that
would require experimental testing and thereby minimize the amount of time, cost, and effort
applied to drugs during their development. This article reviews how CADD and molecular
docking techniques are used to develop drug candidates targeting NDs. It describes several
therapeutically relevant targets of new drug treatments for NDs. The limitations associated
with CADD and molecular docking techniques are also referenced; however, CADD will
continue to be a major asset in the discovery process of new drugs for NDs.
Keywords: Alzheimer's disease; Pa